الهيدروكسي يوريا في علاج فقر الدم المنجلي

This study aims to assess the laboratory and clinical benefits of hydroxyurea in the treatment of sickle cell disease. This study includes (50 ) patients of SCD who had reported at least three painful crises in the previous year, or had reported at least three transfusions or hospitalization in a year, or who had a history of stroke, acute chest syndrome or splenic sequestration, or who had systemic sever anemia. Hydroxyurea was gradually increased from an initial dose of 15 mg / kg / d to 30 mg / kg / d. These patients were monitored by 3-month visits for one year to assess laboratory changes and clinical efficacy. Significant hematologic changes included increase in (HB - MCV- HBF) and decrease in HBS. an‎d there was decrease in the number of transfusions, and painful crises. However, there were five patients who did not show any response to the treatment and the HBF concentration did not increase more than 15 % after a treatment for one year.